News | July 06, 2012

New Study Shows Brain SPECT Imaging Enhances Clinical Psychiatric Practice

Study reports 79 percent of diagnosis/treatment differed after review of brain SPECT images

July 6, 2012 — A new study titled “Specific Ways Brain SPECT Imaging Enhances Clinical Psychiatric Practice” was published June in the Journal of Psychoactive Drugs. It reveals how brain SPECT (single photon emission computed tomography) imaging can help clinicians more accurately diagnose and treat a wide variety of mental conditions by looking at the organ responsible for the decision-making, behaviors and overall cognitive functioning.

Co-authored by Daniel G. Amen, M.D., founder of Amen Clinics Inc; Kristen Willeumier, Ph.D. and Joseph Annibali, M.D., the study asked seven board-certified psychiatrists to evaluate 109 patients' files without the SPECT images and give their professional diagnosis and recommended treatment. After they saw the SPECT scans, 79 percent of the diagnosis and/or treatment would have been different. Additionally 22 percent of the patients showed unexpected brain injury and/or toxicity, while 60 percent showed new targets for medication or supplements.

"The SPECT images help the clinician understand where the brain is not functioning properly, so they can give a more accurate diagnosis and treatment offering," said Amen. He has conducted more than 73,000 SPECT scans on patients from 90 countries in the last 20 years.

"In our study, the use of SPECT neuroimaging modified the diagnostic thinking and led clinicians to make different, specific treatment recommendations in a high percentage of cases," wrote Amen, a board-certified child and adult psychiatrist.

Brain SPECT imaging is a form of neuroimaging that reveals the underlying physiology of emotional, behavioral and cognitive disorders such as anxiety, depression, ADD, memory loss, Alzheimer's, addiction, autism, seizures, strokes, toxic exposure and post-traumatic stress disorder.

For more information: www.amenclinics.com

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Icon Launches New Clinical Trial Patient Engagement Platform
Technology | Patient Engagement | May 14, 2019
Icon plc announced the release of its web-based clinical trial patient engagement platform, to provide patients with...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...